Clinical trial register · China

Clinical Trials in Wuhan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC

19187

Studies in scope

all four open statuses

11790

Recruiting now

open to new participants

2028

Lead sponsors

across recruiting studies

Top sites

Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343

Trials with a site in Wuhan

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Recruiting

Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma

NCT06383520Malignant Neoplasm of Liver

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Early Phase 1

100

Wuhan

2023-09-30

Recruiting

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

NCT05997602Langerhans Cell Histiocytosis, LCH

DrugLuvometinib

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2

Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Chengdu, Hangzhou

2023-09-28

Active, closed

A Study of ADRX-0706 in Select Advanced Solid Tumors

NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer

Adcentrx Therapeutics

Phase 1

144

Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan

2023-09-26

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

NCT05981703Advanced Solid Tumor, Solid Tumor

DrugTislelizumab

BeOne Medicines

Phase 1

337

Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu

2023-09-21

Recruiting

Recurrent High Grade Glioma Treated by LITT

NCT06161610Recurrent High Grade Glioma

Beijing Tiantan Hospital

Not applicable

135

Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai

2023-09-19

Recruiting

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

NCT06064812Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV, ER+/HER2- Breast Cancer

DrugFWD1802

Forward Pharmaceuticals Co., Ltd.

Phase 1/2

Hefei, Guangzhou, Huizhou, Nanning, Luoyang, Xinxiang, Zhengzhou, Wuhan

2023-09-12

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Changsha, Hohhot

2023-09-11

Recruiting

A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo

NCT06000956Ankylosing Spondylitis

Tasly Pharmaceutical Group Co., Ltd

Phase 3

408

Beijing, Lanzhou, Shijiazhuang, Luoyang, Wuhan, Suzhou, Nanchong, Tianjin

2023-09-11

Recruiting

Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions

NCT06039917Artificial Intelligence, Surveillance

Renmin Hospital of Wuhan University

Not applicable

1,460

Quanzhou, Wuhan, Shanghai

2023-09-10

Recruiting

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

NCT05860465Locally Advanced or Metastatic Breast Cancer

DrugSPH4336

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 2/3

254

Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Wuhan, Nanjing

2023-09-08

Active, closed

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

NCT05979961Nasopharyngeal Carcinoma

DrugGemcitabine and cisplatin

Sun Yat-sen University

Phase 3

464

Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan, Changsha

2023-09-07

Recruiting

OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors

NCT07382531Solid Tumor

DrugOH2

Binhui Biopharmaceutical Co., Ltd.

Phase 1/2

Wuhan

2023-09-07

Recruiting

Correlation of Memory CD8+ T Cells With Sepsis Severity and Mortality: a Single-center, Unblinded, Prospective, Non-interventional, Observational Study

NCT05875740Sepsis, Inflammatory Response

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

Wuhan

2023-09-06

Recruiting

Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction

NCT06366529Renal Insufficiency, Chronic

Zhen Li

Observational

500

Wuhan

2023-09-01

Recruiting

The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

NCT06050109Breast Cancer Female, Endocrine Therapy

Hongmei Zheng, PhD

Observational

1,200

Wuhan

2023-09-01

Recruiting

Exploring of Serum Biomarkers of Delirium After Cardiovascular Surgery

NCT06007755Delirium

Huazhong University of Science and Technology

Observational

113

Wuhan

2023-09-01

Recruiting

Effects of Acupoint Massage Around Eyes on Ocular Biological Indexes

NCT06293196Investigating the Effects of Periocular Acupressure on Ocular Biological Indicators

Zhongnan Hospital

Not applicable

Wuhan

2023-09-01

Active, closed

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398Metastatic Castrate-sensitive Prostate Cancer

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

420

Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan

2023-08-31

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

DrugOlverembatinib

Ascentage Pharma Group Inc.

Phase 3

350

Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu

2023-08-31

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an

2023-08-31

Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD

Alexion Pharmaceuticals, Inc.

Observational

200

Beijing, Guangzhou, Henan, Shanghai, Sichuan, Wuhan

2023-08-30

Active, closed

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

NCT05995964Atopic Dermatitis

DrugTilrekimig

Pfizer

Phase 2

507

Beijing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanchang

2023-08-22

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT06355934ATTR Amyloidosis

AstraZeneca

Observational

52,121

Beijing, Changsha, Chengdu, Guangzhou, Wuhan

2023-08-21

Active, closed

Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)

NCT06577792Non Small Cell Lung Cancer

Sun Yat-sen University

Not applicable

620

Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing

2023-08-16

Active, closed

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555Primary Immune Thrombocytopenia (ITP)

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

Wuhan, Beijing, Jinan

2023-08-16

Active, closed

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

NCT06858618Safety, Antitumor Activity, PK Profile

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2

Wuhan

2023-08-16

Recruiting

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

NCT06015048HER2-expressing Advanced Solid Tumors

DrugsPyrotinib·Trastuzumab Rezetecan

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2

364

Hefei, Beijing, Chongqing, Nanning, Shijiazhuang, Harbin, Zhengzhou, Wuhan

2023-08-11

Active, closed

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

NCT05909397Breast Cancer

DrugsVepdegestrant·Letrozole

Pfizer

Phase 3

Beijing, Guangzhou, Wuhan, Xi'an

2023-08-09

Active, closed

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

NCT05896124Primary Biliary Cholangitis (PBC)

DrugPleacbo

Cascade Pharmaceuticals, Inc

Phase 2

Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Zhenjiang, Changchun

2023-08-07

Active, closed

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

NCT06001151Carcinoma, Non-Small-Cell Lung

DrugsCadonilimab·Pemetrexed·Carboplatin

Qian Chu

Phase 2

Wuhan

2023-08-07

Active, closed

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

NCT05896137Primary Sclerosing Cholangitis

DrugPleacbo

Cascade Pharmaceuticals, Inc

Phase 2

Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou

2023-08-07

Recruiting

Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing

NCT06413212Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer

Liu Huang

Observational

Wuhan

2023-08-04

Recruiting

Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

NCT06101888Aortic Regurgitation

Peijia Medical Technology (Suzhou) Co., Ltd.

Not applicable

116

Beijing, Fuzhou, Xiamen, Guangzhou, Guangdong, Haerbin, Wuhan, Changsha

2023-08-01

Active, closed

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients

NCT05901987SMA II

GeneCradle Inc

Phase 1/2

Beijing, Chengdu, Chongqing, Wuhan

2023-08-01

Recruiting

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

NCT06717880Advanced Malignancies

DrugsLenvatinib·Bevacizumab

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1

260

Wuhan

2023-07-28

Active, closed

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643Systemic Lupus Erythematosus

DrugUpadacitinib

AbbVie

Phase 3

1,014

Bengbu, Beijing, Xiamen, Guangzhou, Shantou, Nanning, Luoyang, Wuhan

2023-07-25

By invitation

Investigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision-related Complications After Breast Reconstruction Surgery

NCT06258863Breast Neoplasm Female

Hubei Cancer Hospital

Observational

300

Wuhan

2023-07-18

Not yet open

Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL

NCT05918276CLL/SLL

Nanfang Hospital, Southern Medical University

Phase 2

Wuhan, Changsha

2023-07-15

Recruiting

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

NCT05911217Pancreatic Cancer

DrugCT041 autologous CAR T-cell

CARsgen Therapeutics Co., Ltd.

Phase 1

Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou

2023-07-11

Recruiting

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

NCT05886920Advanced Solid Tumors With MAPK Pathway Mutations

DrugD3S-001

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou

2023-07-10

Active, closed

To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A

NCT07548411Severe Hemophilia A

DrugGS1191-0445

Gritgen Therapeutics Co., Ltd.

Phase 1/2

Wuhan, Tianjin

2023-07-10

Active, closed

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy

DrugZigakibart

Novartis Pharmaceuticals

Phase 3

383

Hefei, Beijing, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan

2023-07-06

Recruiting

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

NCT05919030Esophageal Squamous Cell Carcinoma

DrugsNab-paclitaxel·Tislelizumab·Cisplatin

Renmin Hospital of Wuhan University

Phase 3

155

Wuhan

2023-07-01

Active, closed

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769Chronic Obstructive Pulmonary Disease

Hoffmann-La Roche

Phase 3

2,000

Hefei, Beijing, Zunyi, Wuhan, Xuzhou, Pingxiang, Shanghai, Zigong

2023-06-28

Active, closed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

NCT05627063Solid Tumor

Abbisko Therapeutics Co, Ltd

Phase 1

169

Chongqing, Luoyang, Zhengzhou, Wuhan, Changsha, Hohhot, Nanchang, Changchun

2023-06-26

Recruiting

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

NCT05747729Neuroendocrine Carcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1/2

Wuhan

2023-06-21

Active, closed

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

NCT05913037Neurofibromatosis 1, Plexiform Neurofibroma, NF1

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3

167

Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu

2023-06-20

Recruiting

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

NCT06168786Colorectal Cancer

DrugsFruquintinib·Cadonilimab

Huazhong University of Science and Technology

Phase 2

Wuhan

2023-06-20

Recruiting

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

NCT05830500Medullary Thyroid Cancer

DrugAnlotinib hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 4

360

Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan

2023-06-19

Recruiting

Epidemiology and Risk Factors of Uterine Fibroids in China

NCT05840042Uterine Fibroid

Wenwen Wang

Observational

20,000

Wuhan

2023-06-19

Recruiting

Helical Tomotherapy in Multiple Myeloma

NCT05970198Multiple Myeloma

Fuling Zhou

Not applicable

Wuhan

2023-06-14

Active, closed

Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors

NCT05700084Advanced Solid Tumor

DrugsUtidelone·Capecitabine

Beijing Biostar Pharmaceuticals Co., Ltd.

Phase 1/2

Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan

2023-06-09

Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

NCT05862285Cancer

DrugsTiragolumab and Atezolizumab·Divarasib·Tiragolumab·Ipatasertib

Hoffmann-La Roche

Phase 3

200

Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou

2023-06-01

Recruiting

The Effects of Uterine Fibroids on Pregnancy in Women

NCT06020924Female Infertility, Uterine Fibroid

Wenwen Wang

Observational

1,658

Wuhan

2023-06-01

Not yet open

Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients

NCT05894850Artificial Intelligence, Surveillance

Renmin Hospital of Wuhan University

Not applicable

1,644

Wuhan

2023-06-01

By invitation

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

NCT06186804cGvHD

DrugPimicotinib

Abbisko Therapeutics Co, Ltd

Phase 2

Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou

2023-05-30

Recruiting

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

NCT05859750Pancreatic Cancer

Drugs5-Fluorouracil/Leucovorin·Cadonilimab·Irinotecan·Nab-paclitaxel

Akeso

Phase 2

Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou

2023-05-25

Active, closed

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

NCT05879055Neuroendocrine Neoplasm

DrugsPumitamig·Folfox

Biotheus Inc.

Phase 2

Chongqing, Fuzhou, Harbin, Zhengzhou, Jingzhou, Wuhan, Changsha, Yongzhou

2023-05-17

Recruiting

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer

Zhejiang University

Not applicable

568

Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha

2023-05-14

Recruiting

The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis

NCT05757505Intracranial Atherosclerosis

Ton-Bridge Medical Tech. Co., Ltd

Not applicable

200

Luoyang, Wuhan, Nanjing, Nanchang, Changchun, Dalian, Baotou, Kunming

2023-05-11

Recruiting

A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

NCT06000917Breast Cancer, Neoadjuvant

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2

Wuhan

2023-05-11

Recruiting

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

NCT05976997Newly Diagnosed Peripheral T-cell Lymphoma

Liling Zhang

Phase 2

Wuhan

2023-05-08

Active, closed

A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

NCT05773820Advanced Solid Tumors

DrugWJB001

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang

2023-05-05

Recruiting

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

NCT05698459Advanced Liver Cancer

DrugOH2

Binhui Biopharmaceutical Co., Ltd.

Phase 1

Wuhan

2023-05-05

Active, closed

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

NCT05658003Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DrugsARDT·[68Ga]Ga-PSMA-11·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou

2023-05-05

Recruiting

Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

NCT05894369Esophageal Cancer

Renmin Hospital of Wuhan University

Observational

Wuhan

2023-05-04

Recruiting

FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

NCT06988852Colorectal Liver Metastasis (CRLM)

DrugsErbitux·Cetuximab·Bevacizumab

Tongji Hospital

Phase 2

300

Wuhan

2023-05-01

Recruiting

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

NCT05918094Gastric Cancer

DrugSintilimab

Sun Yat-sen University

Phase 3

540

Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai

2023-04-30

Active, closed

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

DrugPimicotinib

Abbisko Therapeutics Co, Ltd

Phase 3

Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan

2023-04-27

Recruiting

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

NCT05741359Non-hodgkin Lymphoma,B Cell

Bioray Laboratories

Phase 1

Wuhan, Tianjin, Hangzhou

2023-04-25

Recruiting

A Study of BPI-460372 in Advanced Solid Tumor Patients

NCT05789602Advanced Solid Tumor

Betta Pharmaceuticals Co., Ltd.

Phase 1

Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou

2023-04-24

Active, closed

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

NCT05816252Non-small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Osimertinib·Carboplatin·Pembrolizumab

Klus Pharma Inc.

Phase 2

356

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2023-04-19

Recruiting

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

NCT05686642Acute Ischemic Stroke

DrugLT3001 Drug

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 2

300

Beijing, Guangzhou, Luoyang, Hengshui, Daqing, Wuhan, Baotou, Huai'an

2023-04-06

Active, closed

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05704049Relapsed/Refractory Multiple Myeloma

DrugsMontelukast·Diphenhydramine·Acetaminophen·Isatuximab

Sanofi

Phase 2

118

Changsha, Guangzhou, Nanchang, Shenyang, Tianjin, Wuhan

2023-04-05

Active, closed

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906Biochemically Recurrent Prostate Cancer

DrugDarolutamide

Bayer

Phase 3

985

Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou

2023-04-03

Active, closed

Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.

NCT07011329Nasopharyngeal Carcinoma (NPC)

Hubei Cancer Hospital

Observational

Wuhan

2023-04-01

Active, closed

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

NCT05624554Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Riabni·Ruxience·Truxima

Merck Sharp & Dohme LLC

Phase 3

300

Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha

2023-03-16

Recruiting

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

NCT06010342Solid Tumor

Teligene US

Phase 2

Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha

2023-03-16

Recruiting

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

NCT05687357Gastric Cancer, Gastroesophageal-junction Cancer

DrugsTeysuno·Nab-paclitaxel·Tislelizumab·Oxaliplatin

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

140

Wuhan, Nanjing, Taiyuan

2023-03-15

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2023-03-15

Recruiting

Clinical Observation of CABA System in the Treatment of End-stage Liver Disease With Inflammation

NCT05780190To Evaluate the Clinical Efficacy and Safety of the New ALSS

Qin Ning

Phase 4

Wuhan

2023-03-10

Active, closed

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

NCT05765825Extensive-stage Small-cell Lung Cancer

DrugsSerplulimab·Etoposide·Cisplatin·Carboplatin

Sichuan University

Phase 2

Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang

2023-03-07

Recruiting

Comparison of an Acceleromyography- and Electromyography-based Neuromuscular Monitor With TOF-Watch ® Monitor

NCT05632107Neuromuscular Blockade

Huazhong University of Science and Technology

Observational

100

Wuhan

2023-03-01

Recruiting

Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS)

NCT06110910Childhood Short Stature

DrugsPEG-rhGH·RhGH

Xiaoping Luo

Observational

10,000

Wuhan

2023-03-01

Not yet open

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

NCT05747716Metastatic Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2

Wuhan

2023-02-28

Recruiting

APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

NCT05701306Neuroblastoma, Solid Tumor

DrugsAPG-115·Lisaftoclax

Ascentage Pharma Group Inc.

Phase 1/2

100

Guangzhou, Wuhan, Tianjin

2023-02-28

Not yet open

Evaluating the Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients

NCT05751824Artificial Intelligence, Surveillance

Renmin Hospital of Wuhan University

Not applicable

867

Jiangmen, Wuhan

2023-02-26

Recruiting

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

NCT05817214Cervical Cancer

DrugsAnlotinib·Cadonilimab

Zhongnan Hospital

Phase 2

Wuhan

2023-02-16

Active, closed

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015Metastatic Non-small Cell Lung Cancer

DrugsPegylated filgrastim·Pembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol

Merck Sharp & Dohme LLC

Phase 3

377

Hefei, Beijing, Wanzhou, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Wuhan

2023-02-14

Active, closed

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238Haemophilia A, Haemophilia A With Inhibitors

Novo Nordisk A/S

Phase 3

451

Beijing, Guangzhou, Wuhan, Changsha, Jinan, Chengdu, Tianjin, Huzhou

2023-02-13

Recruiting

Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain.

NCT06290661Postherpetic Neuralgia, Peripheral Neuropathic Pain, Trigeminal Neuralgia

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Not applicable

Wuhan

2023-02-09

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan

2023-02-08

Recruiting

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

NCT05667506B-cell Acute Lymphoblastic Leukemia

DrugSingle of CNCT19

Juventas Cell Therapy Ltd.

Phase 1/2

Hefei, Chongqing, Guangzhou, Wuhan, Nanjing, Xuzhou, Nanchang, Tianjin

2023-02-07

Active, closed

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219Primary Immune Thrombocytopenia

DrugsEltrombopag·Ianalumab

Novartis Pharmaceuticals

Phase 3

152

Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin

2023-02-02

Active, closed

The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection（BROAD）

NCT05659641Aortic Dissection, Aneurysm, Dissecting, Aneurysm, Vascular Diseases

Permed Biomedical Engineering Co., Ltd

Not applicable

259

Hefei, Chongqing, Fuzhou, Shijiazhuang, Harbin, Wuhan, Nanjing, Nanchang

2023-01-18

Active, closed

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

NCT05642780Solid Tumor

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Klus Pharma Inc.

Phase 2

240

Guangzhou, Nanning, Wuhan, Changsha, Changchun, Dalian, Weifang, Xi’an

2023-01-17

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Wuhu, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Shenyang

2023-01-16

By invitation

KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial

NCT05635591EBV-associated Haematologic Neoplasms

Tongji Hospital

Phase 1

Wuhan

2023-01-16

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05702229Gastric Cancer

DrugsSonesitatug Vedotin·Volrustomig·Xelox·Rilvegostomig

AstraZeneca

Phase 2

163

Beijing, Hangzhou, Harbin, Hefei, Kunming, Wuhan, Yinchuan, Zhengzhou

2023-01-16

Recruiting

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

NCT05615974Malignant Tumors

DrugsToripalimab·Rituximab

LaNova Medicines Limited

Phase 1/2

139

Guangzhou, Wuhan, Linyi, Beijing, Shanghai

2023-01-11

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong

2023-01-10

Active, closed

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

NCT05661955Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma

DrugTislelizumab

BeiGene

Phase 1/2

113

Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha

2023-01-09

Recruiting

Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma

NCT05830812Lung Adenocarcinoma, Stage I

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

3,000

Wuhan

2023-01-01

Recruiting

Integrin αvβ6-targeted PET in Malignant Tumors

NCT05835570Malignant Neoplasm, PET/CT, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic

Zhongnan Hospital

Observational

200

Wuhan

2023-01-01

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

Beijing, Lanzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changchun

2022-12-27

Active, closed

First in Human Study of AZD9592 in Solid Tumors

NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

DrugsAZD9592·Osimertinib·Leucovorin·Adrucil

AstraZeneca

Phase 1

190

Beijing, Chongqing, Guangzhou, Wuhan

2022-12-21

Active, closed

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

NCT05469737Myelodysplastic Syndromes

DrugsOnureg·Azacitidine

Bristol-Myers Squibb

Phase 2/3

230

Wuhan

2022-12-14

Active, closed

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303Atherosclerotic Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

7,297

Beijing, Guangzhou, Huizhou, Nanning, Daqing, Harbin, Nanyang, Wuhan

2022-12-14

Recruiting

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

NCT05611801Hemophilia A, Hemophilia B

DrugMarstacimab

Pfizer

Phase 3

100

Beijing, Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin

2022-12-09

Active, closed

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

696

Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai

2022-12-09

Active, closed

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

DrugOpnurasib

Novartis Pharmaceuticals

Phase 2

Wuhan, Changsha, Beijing

2022-12-06

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984Advanced Solid Tumors

DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin

AbbVie

Phase 1

288

Beijing, Wuhan, Shenyang, Shanghai

2022-12-05

Not yet open

Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

NCT03127111Stage III Colorectal Cancer

Renmin Hospital of Wuhan University

Observational

300

Wuhan

2022-12-01

Recruiting

Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis (UC)

NCT05679622Ulcerative Colitis

Biao Zou

Not applicable

Wuhan

2022-12-01

Recruiting

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

NCT06005870Diffuse Large B Cell Lymphoma

DrugZanubrutinib

Huazhong University of Science and Technology

Phase 2

Wuhan

2022-11-26

Recruiting

The Effect of Eyeliner on Tear Composition, Tear Secretion and Tear Film Stability.

NCT05632887Dry Eye

Zhongnan Hospital

Observational

Wuhan

2022-11-20

Active, closed

Transapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

NCT05648825Nonobstructive Hypertrophic Cardiomyopathy

Xiang Wei

Not applicable

100

Wuhan

2022-11-15

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai

2022-11-10

Active, closed

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227Eosinophilic Esophagitis

DrugTezepelumab

AstraZeneca

Phase 3

368

Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan

2022-11-10

Active, closed

Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

NCT05486104Moderate to Severe Ulcerative Colitis

DrugMufemilast

Ganzhou Hemay Pharmaceutical Co., Ltd

Phase 2

Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang

2022-11-08

Recruiting

A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

NCT05579132Acute Lymphoblastic Leukemia

DrugMK-1045

MSD R&D (China) Co., Ltd.

Phase 1/2

203

Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xuzhou, Chengdu

2022-11-01

Recruiting

The Prognosis of Patients After PCI：a Multi-center Study in China

NCT05614050Inflammation

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

2,400

Wuhan

2022-11-01

Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05458219Locally Advanced Unresectable or Metastatic Solid Tumors

DrugsMFOLFOX·IBI343

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1

470

Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha

2022-10-26

Active, closed

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

NCT06166836Solid Tumor

DrugIN10018

InxMed (Shanghai) Co., Ltd.

Phase 1/2

140

Hangzhou, Bengbu, Changsha, Fuzhou, Ganzhou, Nanjing, Wuhan, Xuzhou

2022-10-12

Not yet open

Diagnostic Cervical Conization for Persistent Infection or Integration of HPV

NCT05510830Human Papilloma Virus Infection, Human Papilloma Virus Integration, Cervical Intraepithelial Neoplasia, Cervical Cancer

Tongji Hospital

Not applicable

250

Wuhan

2022-10

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha

2022-09-20

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Chaoyang, Chengdu, Hangzhou, Jinhua, Nanjing, Wuhan

2022-09-19

Active, closed

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368Hypereosinophilic Syndrome

DrugDepemokimab

GlaxoSmithKline

Phase 3

110

Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Suzhou, Wuhan

2022-09-06

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan

2022-09-06

Active, closed

Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma

DrugSonrotoclax

BeOne Medicines

Phase 1/2

125

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Zhengzhou, Wuhan

2022-09-05

Recruiting

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT05168566Non-small Cell Lung Cancer

DrugSutetinib Maleate

Teligene US

Phase 2

128

Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha

2022-09-01

Active, closed

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

NCT05459844Neuroendocrine Tumors

DrugsLutetium[177Lu] Oxodotreotide·Octreotide·Octreotide LAR

Sinotau Pharmaceutical Group

Phase 3

196

Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun

2022-08-31

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing

2022-08-30

Active, closed

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

DrugJNJ-80948543

Janssen Research & Development, LLC

Phase 1

167

Chongqing, Guangzhou, Tianjin, Wuhan

2022-08-18

Active, closed

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS

DrugsNorditropin·Somapacitan

Novo Nordisk A/S

Phase 3

412

Beijing, Guangzhou, Liuzhou, Sanya, Zhengzhou, Wuhan, Changsha, Changchun

2022-08-10

Recruiting

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors

NCT05461768Breast Cancer, Locally Advanced or Metastatic Solid Tumor

DrugT-Bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

348

Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou

2022-08-09

Active, closed

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases

DrugIDRX-42

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1

276

Beijing, Guangzhou, Wuhan

2022-08-03

Recruiting

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145KRAS P.G12C

DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

442

Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou

2022-08-03

Recruiting

Cardiorespiratory Fitness After Lobectomy Versus Sublobar Resection

NCT07841249Lung Cancer (NSCLC)

Tongji Hospital

Observational

604

Wuhan

2022-08-01

Recruiting

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595Advanced or Metastatic Colorectal Cancer

DrugsAmivantamab·Fluorouracil·Leucovorin·Irinotecan

Janssen Research & Development, LLC

Phase 1/2

225

Dalian, Guangzhou, Hangzhou, Wuhan

2022-07-29

Active, closed

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

NCT05899049Carcinoma, Renal Cell

DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda

Merck Sharp & Dohme LLC

Phase 3

251

Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang

2022-07-27

Active, closed

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

NCT05502393Advanced Solid Tumors

DrugsJS107·Toripalimab·Capecitabine·Oxaliplatin

Shanghai Junshi Bioscience Co., Ltd.

Phase 1

133

Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin

2022-07-26

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsNemtabrutinib·Zilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 2

189

Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun

2022-07-21

Active, closed

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

452

Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing

2022-07-14

Active, closed

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

NCT05226871Breast Cancer, Head and Neck Cancer

DrugsPalbociclib·Letrozole·Fulvestrant·Cetuximab

Pfizer

Phase 2

Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang

2022-07-07

Active, closed

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 1

160

Hefei, Beijing, Chaoyang, Chongqing, Harbin, Zhengzhou, Wuhan, Xuzhou

2022-06-30

Active, closed

Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC

NCT05459415Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Resection Margin

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Not applicable

Wuhan

2022-06-22

Active, closed

A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

NCT05235516Locally Advanced Cervical Carcinoma

DrugsCadonilimab·Cisplatin

Akeso

Phase 3

636

Beijing, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou

2022-06-21

Recruiting

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

NCT05445011Acute Myeloid Leukemia

DrugsFludarabine·Cyclophosphamide

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1

Wuhan

2022-06-14

Recruiting

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

NCT05365581Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma

DrugsASP2138·Ramucirumab·Fluorouracil·Leucovorin

Astellas Pharma Global Development, Inc.

Phase 1

398

Guangzhou, Zhengzhou, Wuhan, Shanghai, Hangzhou

2022-06-07

Active, closed

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors

NCT05339685Breast Cancer

DrugBL-M02D1

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

Bengbu, Guangzhou, Guilin, Wuhan, Yueyang, Changchun, Hangzhou

2022-05-20

Active, closed

A Study of AL8326 in Non-Small Cell Lung Cancer

NCT06794957Non-small Cell Lung Cancer

DrugAL8326

Advenchen Laboratories, LLC

Phase 1

158

Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou

2022-05-19

Recruiting

Multicenter Prospective Cohort of Sepsis and ARDS in China

NCT07863908Sepsis, ARDS

Shanghai Zhongshan Hospital

Observational

6,000

Xiamen, Guangzhou, Zhengzhou, Wuhan, Jiangyin, Wuxi, Yangzhou, Yixing

2022-05-01

Active, closed

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT05171647Non-Hodgkin Lymphoma

DrugsMosunetuzumab·Polatuzumab Vedotin·Tocilizumab·Rituximab

Hoffmann-La Roche

Phase 3

208

Chengdu, Fuzhou, Guangzhou, Tianjin, Wuhan, Zhengzhou

2022-04-25

Recruiting

Transapical Beating-heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy

NCT05332691Hypertrophic Obstructive Cardiomyopathy

Xiang Wei

Not applicable

1,000

Wuhan

2022-04-15

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Bengbu, Hefei, Wuhu, Beijing, Guangzhou, Harbin, Wuhan, Changsha

2022-04-14

Recruiting

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

NCT0538869519 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors

Hebei Senlang Biotechnology Inc., Ltd.

Phase 1

100

Wuhan

2022-04-08

Recruiting

National Registry and Cohort Study of Pulmonary Vascular Disease

NCT05368467Pulmonary Arterial Hypertension

Nanjing First Hospital, Nanjing Medical University

Observational

1,000

Guangzhou, Nanjing, Tianjin, Beijing, Changsha, Chendu, Shenyang, Wuhan

2022-03-29

Active, closed

STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation

NCT05352074Slow Transit Constipation, Surgery

Third Military Medical University

Not applicable

252

Yuzhong, Lanzhou, Wuhan, Nanjing, Shengyang, Qingdao, Pudong, Xi’an

2022-03-27

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide

Merck Sharp & Dohme LLC

Phase 3

460

Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou

2022-03-24

Active, closed

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051Neoplasms

DrugsRemzistotug·Nelistotug·Belrestotug·Ris-Rez

GlaxoSmithKline

Phase 1

152

Chengdu, Jinan, Shanghai, Wuhan

2022-03-22

Recruiting

Fecal Microbiota Transplantation in Pediatric Crohn's Disease

NCT05321745Crohn Disease

Biao Zou

Not applicable

Wuhan

2022-03-22

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT05219721Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia

DrugCar-T

Chunrui Li

Phase 1

Wuhan

2022-03-17

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan

2022-03-15

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

Beijing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Wuhan, Changsha

2022-03-15

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

NCT05201248B-Cell Non-Hodgkin Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 1/2

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Xuzhou

2022-03-10

Active, closed

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470Extensive-stage Small-cell Lung Cancer

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 2

187

Changchun, Changsha, Chengdu, Guangdong, Hangzhou, Linyi, Shanghai, Wuhan

2022-03-09

Active, closed

A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

NCT05300932Systemic Sclerosis

DrugsBaricitinib·Cytoxan·Cyclophosphamide

Tongji Hospital

Phase 4

Wuhan

2022-03-08

Recruiting

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

NCT05112991Advanced Endometrial Cancer

DrugsEnvafolimab·Lenvatinib

3D Medicines (Sichuan) Co., Ltd.

Phase 2

108

Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yueyang

2022-03-04

Recruiting

THE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein

NCT05194423Tricuspid Valve Regurgitation

Changhai Hospital

Not applicable

150

Beijing, Guangzhou, Wuhan, Xi'an, Shanghai, Chengdu, Hangzhou

2022-03-01

Recruiting

CXCR4-targeted PET/CT Imaging in Hematological Malignancies

NCT05255926CXCR4, PET/CT, Hematological Malignancy

Drug68Ga-Pentixafor

Zhongnan Hospital

Not applicable

300

Wuhan

2022-03-01

Recruiting

A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.

NCT05255978the Effect of NAFLD on CHB

Qin Ning

Observational

10,000

Wuhan

2022-02-24

Active, closed

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

NCT05285826Papillomavirus Infections

DrugNonavalent HPV vaccine

Merck Sharp & Dohme LLC

Phase 3

8,100

Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha

2022-02-18

Active, closed

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

NCT05194995Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer

DrugsGlecirasib·Cetuximab

Allist Pharmaceuticals, Inc.

Phase 1/2

Beijing, Nanning, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang

2022-02-17

Recruiting

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

NCT05263206Pruritus

DrugsFexofenadine·Dupilumab

Sanofi

Phase 3

284

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan

2022-02-15

Active, closed

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

NCT05104775Hematologic Malignancies

DrugGNC-035

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

Guangzhou, Guiyang, Shijiazhuang, Wuhan, Shenyang, Shanghai, Yibin

2022-02-09

Active, closed

Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma

NCT07444905HCC - Hepatocellular Carcinoma, Machine Learning, Evaluation

Tongji Hospital

Observational

1,523

Wuhan

2022-02-01

Active, closed

Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies

NCT06220097B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2

Wuhan

2022-02-01

Recruiting

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia

Chongqing Precision Biotech Co., Ltd

Phase 2

100

Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang

2022-01-26

Active, closed

Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial

NCT05353816End-stage Heart Failure

Shenzhen Core Medical Technology CO.,LTD.

Not applicable

Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou

2022-01-26

Recruiting

PROfiling Based Endometrial Cancer Adjuvant Therapy

NCT05179447Endometrial Cancer Stage I, Endometrial Cancer Stage II

Women's Hospital School Of Medicine Zhejiang University

Not applicable

590

Wuhan, Jinan, Hangzhou, Beijing, Changsha, Guangzhou, Ningbo, Shanghai

2022-01-24

Active, closed

China S3 PMS: SAPIEN 3 China Post Market Registry Study

NCT05168826Aortic Stenosis, Severe

Edwards Lifesciences

Observational

250

Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Shanghai, Xi’an

2022-01-24

Recruiting

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

NCT05206890Ovarian Cancer

DrugFluzoparib

Tongji Hospital

Observational

490

Wuhan

2022-01-14

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma

DrugsGranulocyte Colony-Stimulating Factor·Zilovertamab vedotin·Riabni·G-Csf

Merck Sharp & Dohme LLC

Phase 2/3

290

Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun

2022-01-14

Recruiting

Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

NCT05141253Cancer

DrugRD133

Tongji Hospital

Early Phase 1

Wuhan

2022-01-12

Active, closed

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

NCT05144243Acute Myeloid Leukemia (AML)

DrugsVenclexta·Azacitidine·Venetoclax

AbbVie

Phase 4

Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang

2022-01-06

Recruiting

Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

NCT04662918GastroIntestinal Bleeding

Xingshun Qi

Observational

3,000

Beijing, Fuzhou, Wuhan, Nanchang, Dalian, Shenyang, Xi'an, Jinan

2022-01-01

Recruiting

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

NCT05541367Breast Cancer, TNBC - Triple-Negative Breast Cancer, Estrogen-receptor-negative Breast Cancer

Tongji Hospital

Observational

Wuhan

2021-12-31

Recruiting

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 2

Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou

2021-12-28

Active, closed

A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC

NCT05054439Head and Neck Squamous Cell Carcinoma

DrugsSI-B001·Docetaxel·Paclitaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2

Guilin, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou

2021-12-22

Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT05067283Advanced Solid Tumors

DrugsCalderasib·Leucovorin·Cetuximab·Adrucil

Merck Sharp & Dohme LLC

Phase 1

830

Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou

2021-12-17

Active, closed

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

NCT05070858Generalized Myasthenia Gravis

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

288

Beijing, Fuzhou, Guangdong, Guangzhou, Shenzhen, Haikou, Wuhan, Changsha

2021-12-14

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,007

Wuhan, Nanjing, Yinchuan, Taiyuan, Hangzhou, Wenzhou, Beijing, Shanghai

2021-12-13

Recruiting

Corheart 6: Long-term Cohort Study

NCT07094919Heart Failure

China National Center for Cardiovascular Diseases

Not applicable

160

Shenzhen, Zhengzhou, Wuhan, Nanjing, Beijing, Shanghai

2021-12-12

Active, closed

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

NCT05112965Neoplasms

DrugsXtandi·Enzalutamide·Tecentriq·Avastin

Hoffmann-La Roche

Phase 3

Guangzhou, Harbin, Wuhan, Jinan, Hangzhou, Beijing, Changchun, Changsha

2021-12-01

Recruiting

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

NCT05194982Locally Advanced or Metastatic Solid Tumor

DrugIza-bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

570

Chongqing, Guangzhou, Wuhan, Changsha, Shanghai, Taiyuan

2021-11-29

Recruiting

Multicenter Study on Postoperative Urinary and Sexual Function During Laparoscopic Functional Total Mesorectum Excision

NCT05049317Rectal Cancer

Renmin Hospital of Wuhan University

Not applicable

Wuhan

2021-11-24

Active, closed

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428Atherosclerotic Cardiovascular Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

17,004

Beijing, Foshan, Guangzhou, Nanning, Harbin, Jingzhou, Wuhan, Changsha

2021-11-23

Active, closed

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04812925Primary Immune Thrombocytopenia

DrugEfgartigimod PH20

argenx

Phase 3

173

Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou

2021-11-17

Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127Hemophilia A, Hemophilia B

DrugMarstacimab

Pfizer

Phase 3

245

Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin, Beijing

2021-11-17

Active, closed

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052Differentiated Thyroid Cancer (DTC)

DrugsDabrafenib·Trametinib

Novartis Pharmaceuticals

Phase 3

153

Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Xuzhou, Changchun, Chengdu

2021-11-15

Recruiting

Immune Score Based Radiomics in Nasopharyngeal Carcinoma

NCT05126160Nasopharyngeal Carcinoma

Zhejiang Cancer Hospital

Observational

494

Wuhan, Ningbo, Wenzhou, Hangzhou

2021-11-05

Active, closed

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

NCT04684108Relapsed or Refractory Multiple Myeloma, Hematological Malignancy

DrugSG301

Hangzhou Sumgen Biotech Co., Ltd.

Phase 1

Bengbu, Beijing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Xiangyang, Wuxi

2021-11-04

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Beijing, Fuzhou, Harbin, Wuhan, Changsha, Nanjing, Taizhou, Jinan

2021-10-25

Active, closed

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239Neoplasms

DrugsEzabenlimab·Pembrolizumab

Boehringer Ingelheim

Phase 1

151

Bengbu, Changsha, Fuzhou, Guangzhou, Wuhan

2021-10-18

Recruiting

Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling

NCT04936620Spinal Cord Injuries

St George's, University of London

Not applicable

222

Wuhan

2021-10-08

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu

2021-10-06

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing

2021-10-04

Recruiting

First in Human, Dose Escalation Study of AN4005

NCT04999384Advanced Solid Tumor, Advanced Lymphoma

Adlai Nortye Biopharma Co., Ltd.

Phase 1

Beijing, Harbin, Wuhan

2021-09-27

Active, closed

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

282

Hefei, Beijing, Guangzhou, Wuhan, Changsha, Hohhot, Nanchang, Shenyany

2021-09-23

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Fuzhou, Wuhan, Changchun, Hangzhou, Beijing

2021-09-22

Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605Relapsed/Refractory Multiple Myeloma

DrugsSonrotoclax·Carfilzomib·Pomalidomide·Daratumumab

BeOne Medicines

Phase 1/2

246

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan

2021-09-16

Recruiting

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

NCT04986423Metastatic Castration-Resistant Prostate Cancer

DrugsZEN003694·Xtandi·Enzalutamide

Zenith Epigenetics

Phase 2

200

Hefei, Chongqing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Shenyang

2021-09-08

Recruiting

Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood

NCT06082765Cervical Cancer

Zhongnan Hospital

Observational

10,000

Wuhan

2021-09-01

Active, closed

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811Non Small Cell Lung Cancer

DrugTaletrectinib

Nuvation Bio Inc.

Phase 2

217

Beijing, Zhengzhou, Shanghai, Changsha, Chengdu, Jinan, Wuhan

2021-09-01

By invitation

Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)

NCT06101940Myotonic Dystrophy 1

Huashan Hospital

Observational

1,000

Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou

2021-08-01

Recruiting

Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis

NCT06357741Knee Osteoarthritis

DrugDenosumab

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

Wuhan

2021-08-01

Active, closed

PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

NCT04907370Nasopharyngeal Carcinoma

DrugsGemcitabine·Cisplatin

Sun Yat-sen University

Phase 3

532

Beijing, Chongqing, Foshan, Guangzhou, Nanning, Guiyang, Wuhan, Changsha

2021-08-01

Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618C3G

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Guangzhou, Wuhan, Beijing, Shanghai

2021-07-28

Active, closed

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

NCT04928807Rectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 3

231

Wuhan

2021-07-20

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04961567Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

562

Beijing, Dongguan, Guangzhou, Shenzhen, Haikou, Changsha, Zhuzhou, Wuhan

2021-07-16

Recruiting

Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial

NCT04948749ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke

Beijing Tiantan Hospital

Not applicable

358

Beijing, Cangzhou, Tangshan, Xingtai, Wuhan, Baotou, Hohhot, Tongliao

2021-07-02

Recruiting

The Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery (SMILE)

NCT05113017The Efficacy and Safety of SBRT in MPLC

Fang Wu

Observational

Changsha, Wuhan

2021-07-01

Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer

DrugGivastomig

I-Mab Biopharma US Limited

Phase 1

330

Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai

2021-06-29

Active, closed

A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease

NCT04944043Chronic Graft Versus Host Disease

DrugRovadicitinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2

Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin

2021-06-25

Active, closed

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248Primary Membranous Nephropathy

DrugsDiphenhydramine·Acetaminophen·Tacrolimus·Methylprednisolone

Hoffmann-La Roche

Phase 3

142

Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an

2021-06-25

Recruiting

Perioperative EEG-Monitoring and Postoperative Delirium in Patients Undergoing Cardiovascular Surgery

NCT04832568Delirium

Huazhong University of Science and Technology

Observational

200

Wuhan

2021-06-17

Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm

DrugsPosaconazole·Sonrotoclax·Azacitidine

BeOne Medicines

Phase 1/2

260

Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang

2021-05-24

Active, closed

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622Prostate Cancer

DrugsTalazoparib·Enzalutamide

Pfizer

Phase 3

599

Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing

2021-05-12

Recruiting

RIR and the Impact on Clinical Outcomes in Patients Undergoing PCI

NCT05131750hsCRP

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

1,408

Wuhan

2021-05-06

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362Breast Cancer

DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab

Hoffmann-La Roche

Phase 3

1,188

Chengdu, Chongqing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Xi'an

2021-05-04

Active, closed

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

NCT04683003Thrombotic Thrombocytopenic Purpura (TTP)

DrugTAK-755

Takeda

Phase 3

Beijing, Wuhan, Suzhou, Tianjin

2021-04-14

Recruiting

HANGZHOU Solution in Bicuspid AS Undergoing TAVR

NCT04722796Aortic Stenosis, Aortic Stenosis With Bicuspid Valve

Second Affiliated Hospital, Zhejiang University, School of Medicine

Not applicable

508

Bengbu, Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha

2021-04-12

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Hefei, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Yichang

2021-04-08

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia

DrugNemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

490

Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Zhengzhou, Wuhan

2021-04-05

Recruiting

Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease

NCT06442852Alzheimer Disease, MicroRNAs

Jiajie Chen

Observational

500

Wuhan

2021-04-03

Active, closed

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition

NCT04654468Paroxysmal Nocturnal Hemoglobinuria

DrugCrovalimab

Hoffmann-La Roche

Phase 3

Chengdu, Guangzhou, Tianjin, Wuhan

2021-03-17

Active, closed

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

NCT04562870Myelofibrosis

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 2

112

Beijing, Wuhan, Nantong, Suzhou, Changchun, Hangzhou

2021-03-17

Recruiting

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

NCT04847752Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)

DrugsEvolocumab·Alirocumab·Biweekly·Dabigatran

Tongji Hospital

Observational

1,000

Wuhan

2021-03-01

Active, closed

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638Diffuse Large B-cell Lymphoma

DrugsRituxumab·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

270

Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou

2021-02-23

Recruiting

68Ga-FAPI PET/CT in Malignant Tumors

NCT05034146Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm

Drug68Ga-FAPI

Zhongnan Hospital

Not applicable

500

Wuhan

2021-02-23

Recruiting

Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery

NCT04733820Uterine Cervical Neoplasms, Cervical Cancer

Huazhong University of Science and Technology

Phase 3

340

Wuhan

2021-02-01

Active, closed

A Study of Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon

NCT04826705Drug-coated Balloon, Femoropopliteal Artery Occlusion, Angioplasty

Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

Observational

2,000

Wuhan, Beijing, Chengdu, Hangzhou, Qingdao, Shanghai, Suzhou

2021-02-01

Recruiting

Research on the Mechanism Affecting Progression of Bronchiectasis

NCT05731427Bronchiectasis

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

150

Guiyang, Wuhan, Yichang

2021-02-01

Active, closed

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

NCT04544189Breast Neoplasms

DrugsAlpelisib·Fulvestrant

Novartis Pharmaceuticals

Phase 2

Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing

2021-01-20

Recruiting

Mesogastrium Metastasis in Colon Cancer

NCT04980287Colon Cancer

Jichao Qin

Observational

Wuhan

2021-01-12

Active, closed

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877Endometrial Neoplasms

DrugsDocetaxel·Keytruda·Paclitaxel·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

990

Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Wuhan

2021-01-10

Active, closed

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

NCT04507841Ovarian Cancer

DrugNiraparib

Tongji Hospital

Phase 2

Wuhan

2021-01-08

Active, closed

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

181

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Qingdao, Xi’an

2021-01-04

By invitation

Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma

NCT06730477Lung Adenocarcinoma, EGFR Activating Mutation

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

500

Wuhan

2021-01-01

By invitation

The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma

NCT06647836Squamous Cell Lung Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

1,000

Wuhan

2021-01-01

Active, closed

Optimal Ablation Strategies for Persistent AF With HF

NCT07153718Heart Failure, Persistent Atrial Fibrillation

Xu Liu

Not applicable

300

Anqing, Wuhan, Changshu, Xuzhou, Jinan, Jining, Yuhuan, Shanghai

2021-01-01

Active, closed

Prehabilitation Before Liver Surgery in Older Adults

NCT07877311Preoperative Prehabilitation in Older Adults Undergoing Hepatectomy

Lining Xu

Not applicable

500

Beijing, Shenzhen, Zhengzhou, Wuhan

2021-01-01

Active, closed

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

NCT04666272Melanoma

DrugsDabrafenib·Trametinib

Novartis Pharmaceuticals

Observational

Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Kunming, Hangzhou, Beijing

2020-12-31

Recruiting

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT04684147Relapsed or Refractory Acute Lymphoblastic Leukemia

DrugSingle of CNCT19

Juventas Cell Therapy Ltd.

Phase 2

100

Beijing, Chongqing, Guangzhou, Sanhe, Zhengzhou, Wuhan, Xuzhou, Shanghai

2020-12-24

Recruiting

Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease

NCT03972956Colorectal Cancer, Gastric Cancer, Inflammatory Bowel Diseases, Gastric Ulcer

Renmin Hospital of Wuhan University

Observational

1,000

Wuhan

2020-12-23

Recruiting

Secukinumab Open Label Roll-over Extension Protocol

NCT04638647Autoimmunity, Inflammation

DrugSecukinumab

Novartis Pharmaceuticals

Phase 4

1,000

Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan

2020-12-22

Active, closed

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Neoplasms

DrugsEncorafenib·Zirabev·Erbitux·Xeloda

Pfizer

Phase 3

841

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Nanjing

2020-12-21

Recruiting

Function Integrity of Neck Anatomy in Thyroid Surgery

NCT04666103Thyroid Carcinoma, Thyroid Nodule (Benign), Ablation; Retina

Wuhan University

Not applicable

1,264

Wuhan

2020-12-11

Recruiting

Nomogram to Predict Breast Cancer Related Lymphedema

NCT04665882Breast Cancer, Axillary Lymph Node Dissection, Breast Cancer Related Lymphedema, Axillary Reverse Mapping

Wuhan University

Not applicable

600

Wuhan

2020-12-11

Active, closed

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204Small Cell Lung Cancer

DrugsOlaparib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

672

Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha

2020-12-08

Active, closed

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

NCT04540497IgG4 Related Disease

DrugInebilizumab

Amgen

Phase 3

135

Hohhot, Beijing, Guandong, Shang’ai, Shenyang, Wuhan

2020-12-04

Active, closed

Postoperative Thrombosis Prevention in Patients With CD

NCT04486859Cushing Disease, DVT, Pulmonary Embolism

Huashan Hospital

Not applicable

206

Fuzhou, Guangzhou, Wuhan, Shanghai, Chengdu, Ürümqi, Beijing

2020-12-01

Active, closed

Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

NCT04516616Uterine Cervical Neoplasm, Uterine Cervical Cancer, Cervical Cancer

DrugsAlbumin-Bound Paclitaxel·Cisplatin

Huazhong University of Science and Technology

Phase 2

Wuhan

2020-12-01

Recruiting

Durg Coated Balloon Angioplasty in Infrapopliteal Lesions

NCT05620095Arteriosclerosis, Peripheral Artery Disease, Chronic Limb Threatening Ischemia

Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

Observational

1,000

Beijing, Wuhan, Suzhou, Qingdao, Shanghai, Chengdu, Hangzhou

2020-12-01

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

NCT04576455Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Fulvestrant

Hoffmann-La Roche

Phase 2

303

Changchun, Guangzhou, Linyi, Nanchang, Shanghai, Tianjin, Wuhan, Xi'an

2020-11-27

Active, closed

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

NCT04606472Solid Tumor

DrugSI-B003

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

Beijing, Chongqing, Xiamen, Zhengzhou, Wuhan, Shanghai, Chengdu

2020-11-10

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

281

Beijing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wenzhou, Wuhan

2020-11-03

Recruiting

Effect of Acupuncture on IVF Pregnancy Outcomes for Women With RIF

NCT04533295Repeated Implantation Failure

Huazhong University of Science and Technology

Not applicable

771

Wuhan

2020-11-02

Recruiting

Surgical Intervention for Refractory Granulomatous Lobular Mastitis

NCT04637711Refractory Granulomatous Lobular Mastitis

Wuhan University

Not applicable

300

Wuhan

2020-11-01

Recruiting

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT04586478Non-Hodgkin's Lymphoma

DrugSingle of CNCT19

Juventas Cell Therapy Ltd.

Phase 2

Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Jinan, Shanghai, Chengdu

2020-10-26

Active, closed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan

CARsgen Therapeutics Co., Ltd.

Phase 1/2

192

Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing

2020-10-23

Active, closed

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

NCT04434092Paroxysmal Nocturnal Hemoglobinuria

DrugsCrovalimab·Eculizumab

Hoffmann-La Roche

Phase 3

210

Beijing, Guangzhou, Hangzhou, Nanjing, Nantong, Shanghai, Wuhan

2020-10-08

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha

2020-09-30

Recruiting

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

NCT04501120Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy

DrugsOlverembatinib·Lisaftoclax·Azacitidine

Ascentage Pharma Group Inc.

Phase 1/2

682

Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai

2020-09-28

Recruiting

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)

DrugAtirmociclib

Pfizer

Phase 1/2

430

Beijing, Zhengzhou, Wuhan, Xi’an, Hangzhou

2020-09-23

Recruiting

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

NCT04561557Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis

DrugCyclophosphamide and Fludarabine

Tongji Hospital

Early Phase 1

Wuhan

2020-09-22

Recruiting

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

NCT04462770Dravet Syndrome

DrugClemizole HCl

Epygenix

Phase 3

150

Beijing, Chongqing, Guangzhou, Shenzhen, Guiyang, Wuhan, Changsha, Xuzhou

2020-09-15

Active, closed

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

NCT04401748Myelodysplastic Syndrome (MDS)

DrugsVenclexta·Azacitidine·Venetoclax

AbbVie

Phase 3

531

Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou

2020-09-10

Recruiting

Evaluate the Safety and Clinical Activity of HH2853

NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor

DrugHH2853

Haihe Biopharma Co., Ltd.

Phase 1/2

254

Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing

2020-09-08

Recruiting

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

NCT04494503Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsLisaftoclax·Ibrutinib·Rituximab

Ascentage Pharma Group Inc.

Phase 1/2

123

Beijing, Chongqing, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhenzhou, Wuhan

2020-08-31

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

125

Beijing, Guangzhou, Hangzhou, Wenzhou, Wuhan

2020-08-25

Active, closed

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

NCT04285086Essential Thrombocythemia

DrugsAnagrelide·Besremi

PharmaEssentia

Phase 3

174

Beijing, Chongqing, Guangzhou, Wuhan, Suzhou, Shenyang, Xi'an, Jinan

2020-08-25

Active, closed

Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)

NCT06524427Non Small Cell Lung Cancer

Sun Yat-sen University

Not applicable

1,124

Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing

2020-08-25

Active, closed

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

DrugsParaplatin·Taxol·Olaparib·Etoposide

Merck Sharp & Dohme LLC

Phase 3

870

Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha

2020-07-06

Active, closed

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

996

Hefei, Chongqing, Xiamen, Foshan, Guangzhou, Wuhan, Changsha, Changzhou

2020-06-22

Active, closed

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596Gastric Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Fluorouracil

AstraZeneca

Phase 2

452

Chengdu, Guangzhou, Hefei, Shanghai, Shenyang, Wuhan, Zhengzhou

2020-06-03

Recruiting

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

NCT06084299Liver Cancer

DrugAutologous Tumor Infiltrating Lymphocytes

Zhiyong Huang

Phase 1

Wuhan

2020-05-27

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

NCT05713994Hepatocellular Carcinoma Non-resectable

DrugsBevacizumab Biosimilar IBI305·Donafenib·Sorafenib·Regorafenib

Ze-yang Ding, MD

Observational

300

Quanzhou, Wuhan

2020-05-19

Recruiting

Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing

NCT05520788Hepatocellular Carcinoma, Biliary Tract Cancer

Tongji Hospital

Observational

200

Wuhan

2020-05-01

Recruiting

Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease

NCT05321758Crohn Disease

DrugFecal Microbiota Transplantation

Tongji Hospital

Not applicable

Wuhan

2020-03-22

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT04194944Non-Small Cell Lung Cancer

DrugsSelpercatinib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

261

Beijing, Guangzhou, Harbin, Wuhan, Changsha, Changzhou, Changchun, Shanghai

2020-02-17

Active, closed

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

NCT04170283B-cell Malignancies

DrugsZanubrutinib·Tislelizumab

BeOne Medicines

Phase 3

955

Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing

2020-01-16

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

NCT06195228Advanced Thyroid Cancer Patients Who Received Target Therapy

DrugsPralsetinib·Larotrectinib·Selpercatinib·Entrectinib

Fudan University

Phase 4

800

Fuzhou, Zhengzhou, Wuhan, Hohhot, Shanghai, Shanxi, Hangzhou, Beijing

2020-01-01

Active, closed

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

NCT04165317Non-muscle Invasive Bladder Cancer

DrugsSasanlimab·Bacillus Calmette-Guerin

Pfizer

Phase 3

1,068

Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou

2019-12-30

Recruiting

Perioperative EEG-Monitoring and Emergence Delirium in Children

NCT04091724Delirium

Huazhong University of Science and Technology

Observational

400

Wuhan

2019-12-02

Active, closed

Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.

NCT06248528Hepatocellular Carcinoma

Chen Xiaoping

Not applicable

1,076

Wuhan

2019-12-01

Active, closed

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)

DrugOdronextamab

Regeneron Pharmaceuticals

Phase 2

515

Beijing, Tianjin, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Suzhou

2019-11-13

Active, closed

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

NCT03975647HER2-positive Breast Cancer

DrugsTucatinib·Trastuzumab emtansine

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

466

Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang

2019-10-02

Active, closed

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

DrugsBendamustine·Zanubrutinib·Rituximab

BeOne Medicines

Phase 3

510

Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha

2019-08-20

Active, closed

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

NCT07491211NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Osimertinib, Stereotactic Radiation

DrugOsimertinib

Fudan University

Observational

300

Shanghai, Wuhan

2019-07-19

Recruiting

Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection

NCT03491605EBV Infection

Huazhong University of Science and Technology

Observational

10,000

Wuhan

2019-07-01

Active, closed

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

NCT03913949Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 1

Hefei, Zhengzhou, Wuhan, Tianjin, Hangzhou

2019-06-03

Recruiting

Construction of a Multi-center Clinical Research Collaboration Network for Children with Congenital Heart Disease in China

NCT06885307Congenital Heart Disease (CHD)

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Observational

35,000

Wuhan, Xining, Shanghai, Kunming, Wenzhou, Jinan

2019-06-01

Recruiting

APG-2449 in Patients With Advanced Solid Tumors

NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer

DrugAPG -2449

Ascentage Pharma Group Inc.

Phase 1

165

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou

2019-05-27

Active, closed

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

NCT03930953Lymphoma, Non-Hodgkin

DrugsValemetostat·Tafasitamab·Golcadomide·Obinutuzumab

Celgene

Phase 1/2

438

Beijing, Guangzhou, Zhengzhou, Wuhan, Shenyang, Shanghai, Tianjin

2019-05-20

Active, closed

Clinical Trial of Minimally Invasive Surgery Versus Abdominal Surgery in Patients With Early Stage Cervical Cancer

NCT03955185Uterine Cervical Neoplasm

Huazhong University of Science and Technology

Not applicable

2,000

Wuhan

2019-05-01

Recruiting

Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma

NCT03785743Pancreatic Carcinoma, Laparoscopic, Pancreaticoduodenectomy

Tongji Hospital

Not applicable

200

Wuhan

2019-03-01

Recruiting

Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

NCT03810339Solid Tumor, Advanced Cancer

DrugToripalimab

Sun Yat-sen University

Phase 2

Guangzhou, Guiyang, Wuhan, Dalian

2019-01-15

By invitation

A Randomized Controlled Study of Conservative Treatment of Granulomatous Lobular Mastitis Combined With Psychiatric Disorders

NCT05395949Breast Diseases, Mastitis Granulomatous, Psychiatric Disorder

Wuhan University

Not applicable

Wuhan

2019-01-01

Active, closed

Model Development and Application Based on Renal Pathology Images

NCT07816874Kidney Diseases, Chronic, Glomerular Diseases, Tubulointerstitial Kidney Diseases, IgA Nephropathy (IgAN)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

8,000

Wuhan

2019-01-01

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032High-risk Non-muscle Invasive Bladder Cancer

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,397

Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan

2018-12-24

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun

2018-12-07

Active, closed

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

NCT03562637Triple Negative Breast Cancer

OBI Pharma, Inc

Phase 3

575

Beijing, Guangzhou, Nanning, Harbin, Wuhan, Changsha, Nanjing, Changchun

2018-12-05

Active, closed

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

NCT03706365Prostate Cancer

DrugsAbiraterone acetate·Abemaciclib·Prednisone

Eli Lilly and Company

Phase 2/3

393

Hefei, Wuhu, Lanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha

2018-11-26

Recruiting

Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery

NCT03349762Colorectal Cancer

Xi Shan Wang

Observational

3,060

Shijiazhuang, Harbin, Wuhan, Changsha, Changzhou, Xuzhou, Yangzhou, Anshan

2018-11-02

Active, closed

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744Multiple Myeloma

DrugsPomalidomide·Venetoclax·Dexamethasone

AbbVie

Phase 3

265

Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang

2018-10-22

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing

2018-08-28

Active, closed

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318Atopic Dermatitis

DrugUpadacitinib

AbbVie

Phase 3

1,533

Beijing, Guangzhou, Wuhan, Shenyang, Hangzhou, Changsha, Shanghai

2018-08-09

By invitation

AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities

NCT07410403Multiple Myeloma

Fuling Zhou

Observational

Wuhan

2018-08-01

Recruiting

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

NCT03594422Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult

Ascentage Pharma Group Inc.

Phase 1

100

Guangzhou, Zhengzhou, Wuhan, Beijing, Shanghai

2018-07-11

Recruiting

Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer

NCT03573791Rectal Cancer, Cancer of Rectum, Cancer of the Rectum, Neoplasms, Rectal

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

152

Wuhan

2018-05-21

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Guangzhou, Shijiazhuang, Wuhan, Changsha, Nanchang, Shanghai, Chengdu, Tianjin

2018-04-09

Active, closed

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

747

Beijing, Xiamen, Guangzhou, Wuhan, Changsha, Nanjing, Nanchang, Changchun

2018-03-21

Recruiting

Observing the Efficacy and Safety of Different Drugs Used in Real-world Familial Mediterranean Fever (FMF) Cases

NCT07077473Familial Mediterranean Fever (FMF )

Tongji Hospital

Observational

Wuhan

2018-01-01

Active, closed

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197mCRPC

Pfizer

Phase 3

1,054

Hefei, Beijing, Fuzhou, Xiamen, Wuhan, Lianyungang, Nanjing, Nantong

2017-12-18

Active, closed

BioGlue as an Adjunct for Structural Repair and Hemostasis in Chinese Acute Type A Aortic Dissections Patients

NCT03369977Type A Aortic Dissection

CryoLife, Inc.

Not applicable

202

Beijing, Nanjing, Shanghai, Wuhan, Zhengzhou

2017-11-01

Active, closed

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsBendamustine·Venclexta·Zanubrutinib·Venetoclax

BeiGene

Phase 3

590

Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Zhengzhou, Wuhan

2017-10-31

Active, closed

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02966756Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

DrugsVenclexta·Venetoclax

AbbVie

Phase 2

Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha

2017-10-12

Active, closed

A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

NCT03255694Dwarfism

DrugPEG-somatropin

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 2

360

Beijing, Wuhan, Changsha, Naning, Nanjing, Wuxi, Nanchang, Changchun

2017-05-12

Active, closed

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523Acute Myeloid Leukemia (AML)

DrugsAzacitidine·Venetoclax

AbbVie

Phase 3

443

Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Changchun, Shanghai

2017-02-02

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068Ulcerative Colitis (UC)

DrugUpadacitinib

AbbVie

Phase 3

950

Guangzhou, Shiyan, Wuhan, Changsha, Nanchang, Changchun, Shenyang, Shanghai

2017-01-31

By invitation

Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

NCT06688838Blau Syndrome

DrugsTNFi·Tofacitinib

Tongji Hospital

Observational

Wuhan

2017-01-01

Active, closed

Sympathetic Mapping/ Ablation of Renal Nerves Trial

NCT02761811Hypertension

SyMap Medical (Suzhou), Ltd.

Not applicable

220

Beijing, Chongqing, Shenzhen, Shijiazhuang, Daqing, Wuhan, Nanjing, Xuzhou

2016-06-30

Active, closed

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT02767804Non-small Cell Lung Cancer

DrugsEnsartinib·Crizotinib

Xcovery Holdings, Inc.

Phase 3

290

Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing

2016-06

By invitation

Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease

NCT02751060Coronary Disease

Tongji Hospital

Observational

4,000

Wuhan

2016-04

Active, closed

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms

DrugEntrectinib

Hoffmann-La Roche

Phase 2

534

Harbin, Wuhan, Chengdu, Beijing, Guangzhou, Hangzhou, Shanghai, Shenzhen

2015-11-19

Active, closed

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

NCT02542293Non Small Cell Lung Carcinoma NSCLC

DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine

AstraZeneca

Phase 3

953

Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Shanghai, Ürümqi, Wuhan

2015-11-03

Active, closed

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

NCT02375620Short Stature Children Born Small for Gestational Age (SGA)

DrugPEG-somatropin

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 2

Beijing, Wuhan, Changsha, Wuxi, Nanchang, Changchun, Shanghai, Taiyuan

2015-04-23

Recruiting

AI-Based Prediction of Liver Metastasis in Colorectal Cancer (A Retrospective Study)

NCT07399236Colorectal Cancer Liver Metastases (CRLM)

Tongji Hospital

Observational

1,500

Wuhan

2015-01-01

Active, closed

The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma

NCT01820884Endometrial Neoplasms

Ding Ma

Not applicable

240

Wuhan, Jinan, Hangzhou

2012-11

Active, closed

The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma

NCT01820858Endometrial Neoplasms

DrugsParaplatin·Paclitaxel·Carboplatin

Ding Ma

Phase 3

300

Wuhan, Jinan, Hangzhou

2012-11

Recruiting

Nutrition Support on Outcomes and Cost-effectiveness for Patients at Risk

NCT00289380Malnutrition, Nutritional Risk

Peking Union Medical College

Observational

2,000

Beijing, Chongqing, Guangzhou, Nanning, Shijiazhuang, Tianjin, Wuhan, Nanjing

2005-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/wuhan?page=3

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,343 of those studies with a site in Wuhan.

How many clinical trials are recruiting in Wuhan?

805 of the 1,343 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 223 have not yet opened recruitment, 279 are active but closed to new participants, and 36 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.